Masimo Corporation (NASDAQ:MASI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Masimo Corporation (NASDAQ:MASI) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $191.60.

A number of equities research analysts recently weighed in on the stock. Raymond James Financial decreased their price objective on shares of Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. BTIG Research reiterated a “buy” rating on shares of Masimo in a report on Monday, July 14th. Wall Street Zen lowered shares of Masimo from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Wells Fargo & Company decreased their price objective on shares of Masimo from $205.00 to $190.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Thursday, April 10th.

Masimo Price Performance

Shares of NASDAQ MASI opened at $154.47 on Friday. Masimo has a 1 year low of $101.61 and a 1 year high of $194.88. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.17 and a quick ratio of 1.62. The company’s 50-day moving average is $162.09 and its 200 day moving average is $165.97. The stock has a market capitalization of $8.38 billion, a P/E ratio of -16.85 and a beta of 1.19.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.12. The business had revenue of $372.00 million for the quarter, compared to analysts’ expectations of $367.79 million. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. The business’s revenue was down 24.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.77 earnings per share. On average, sell-side analysts expect that Masimo will post 4.1 earnings per share for the current year.

Insider Activity at Masimo

In related news, COO Bilal Muhsin sold 10,000 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the sale, the chief operating officer directly owned 24,172 shares of the company’s stock, valued at approximately $3,946,804.16. This represents a 29.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 9.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Masimo

A number of hedge funds have recently modified their holdings of the company. FMR LLC raised its holdings in Masimo by 19.8% during the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock worth $1,338,509,000 after purchasing an additional 1,340,836 shares in the last quarter. Durable Capital Partners LP purchased a new stake in shares of Masimo during the 1st quarter worth $187,528,000. Capital Research Global Investors boosted its position in shares of Masimo by 80.5% in the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock worth $405,807,000 after buying an additional 1,094,647 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after buying an additional 943,001 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Masimo by 1,276.9% in the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock worth $156,604,000 after buying an additional 878,587 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.